Self-propelled biohybrids co-deliver oxaliplatin and glucose oxidase for multimodal treatment of colon cancer
{{output}}
As a frontline chemotherapeutic agent for colorectal cancer, oxaliplatin (OXA) exhibits significantly reduced therapeutic efficacy and may induce severe adverse effects, primarily due to limited targeting capacity and impaired drug penetration within the hypox... ...
